Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Peptide deformylase | Starlite/ChEMBL | References |
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Peptide deformylase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein | Peptide deformylase | 183 aa | 155 aa | 22.6 % |
Trichomonas vaginalis | abca6, putative | Peptide deformylase | 183 aa | 162 aa | 25.3 % |
Loa Loa (eye worm) | adipor-like receptor | Peptide deformylase | 203 aa | 163 aa | 23.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.0194 | 0.0391 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.0194 | 0.0391 |
Trypanosoma brucei | DNA topoisomerase ii | 0.0689 | 0.4963 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0558 | 0.3646 | 0.6796 |
Brugia malayi | Probable DNA topoisomerase II | 0.0279 | 0.0853 | 0.5 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0279 | 0.0853 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0213 | 0.0194 | 0.0391 |
Schistosoma mansoni | DNA topoisomerase II | 0.0279 | 0.0853 | 0.5 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0782 | 0.5891 | 0.3533 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0279 | 0.0853 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0689 | 0.4963 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0279 | 0.0853 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.0194 | 0.0391 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0279 | 0.0853 | 0.5 |
Plasmodium vivax | DNA gyrase subunit B, putative | 0.1192 | 1 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0213 | 0.0194 | 0.0391 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0279 | 0.0853 | 0.5 |
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0279 | 0.0853 | 0.5 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0279 | 0.0853 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0279 | 0.0853 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0213 | 0.0194 | 0.0391 |
Plasmodium falciparum | DNA gyrase subunit B | 0.1192 | 1 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0279 | 0.0853 | 0.5 |
Leishmania major | mitochondrial DNA topoisomerase II | 0.0689 | 0.4963 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0279 | 0.0853 | 0.5 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.1192 | 1 | 1 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.0194 | 0.0391 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0558 | 0.3646 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0241 | 0.0479 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0558 | 0.3646 | 0.3053 |
Trypanosoma cruzi | mitochondrial DNA topoisomerase II, putative | 0.0689 | 0.4963 | 1 |
Plasmodium vivax | peptide deformylase, putative | 0.0558 | 0.3646 | 0.3053 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0689 | 0.4963 | 1 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.1192 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.1192 | 1 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.1192 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.9 nM | Inhibition of Streptococcus pneumoniae PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
IC50 (binding) | = 4.5 nM | Inhibition of Staphylococcus aureus PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.